Bausch Health Companies Inc. Recognition of Deferred Revenue
Bausch Health Companies Inc. (BHC) reported Recognition of Deferred Revenue of $8.57 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2012-05-04
- Bausch Health Companies Inc. recognition of deferred revenue for the quarter ending 2012-03-31 was $8.57M, a 79.43% increase year-over-year.
- Bausch Health Companies Inc. recognition of deferred revenue for the quarter ending 2011-12-31 was $4.78M, a 0.00% change year-over-year.
- Bausch Health Companies Inc. recognition of deferred revenue for the quarter ending 2011-09-30 was $4.78M, a 0.00% change year-over-year.
- Bausch Health Companies Inc. recognition of deferred revenue for the quarter ending 2011-06-30 was $4.78M, a 0.00% change year-over-year.
- Bausch Health Companies Inc. recognition of deferred revenue for fiscal 2011 was $19.10M, a 0.00% change from fiscal 2010.
- Bausch Health Companies Inc. recognition of deferred revenue for fiscal 2010 was $19.10M, a 9.91% decline from fiscal 2009.
- Bausch Health Companies Inc. recognition of deferred revenue for fiscal 2009 was $21.20M, a 16.20% increase from fiscal 2008.
- Bausch Health Companies Inc. recognition of deferred revenue for fiscal 2008 was $18.25M.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 6 month | Recognition of Deferred Revenue 9 month | Recognition of Deferred Revenue 12 month |
|---|---|---|---|---|
| 2012-03-31 | $8.57M 10-Q · filed 2012-05-04 | $13.34M derived: sum of 2 quarters · filed 2012-05-04 | $18.12M derived: sum of 3 quarters · filed 2012-05-04 | $22.89M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | $4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $9.55M derived: sum of 2 quarters · filed 2012-02-29 | $14.33M derived: sum of 3 quarters · filed 2012-02-29 | $19.10M 10-K · filed 2012-02-29 |
| 2011-09-30 | $4.78M 10-Q · filed 2011-11-04 | $9.55M derived: sum of 2 quarters · filed 2011-11-04 | $14.33M 10-Q · filed 2011-11-04 | $19.10M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | $4.78M 10-Q · filed 2011-08-08 | $9.55M 10-Q · filed 2011-08-08 | $14.33M derived: sum of 3 quarters · filed 2012-05-04 | $19.10M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | $4.78M 10-Q · filed 2012-05-04 | $9.55M derived: sum of 2 quarters · filed 2012-05-04 | $14.32M derived: sum of 3 quarters · filed 2012-05-04 | $19.10M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | $4.78M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $9.55M derived: sum of 2 quarters · filed 2012-02-29 | $14.33M derived: sum of 3 quarters · filed 2012-02-29 | $19.10M 10-K · filed 2012-02-29 |
| 2010-09-30 | $4.78M 10-Q · filed 2011-11-04 | $9.55M derived: sum of 2 quarters · filed 2011-11-04 | $14.33M 10-Q · filed 2011-11-04 | $19.63M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $4.78M 10-Q · filed 2011-08-08 | $9.55M 10-Q · filed 2011-08-08 | $14.85M derived: sum of 3 quarters · filed 2012-02-29 | $20.15M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $4.78M 10-Q · filed 2011-05-10 | $10.07M derived: sum of 2 quarters · filed 2012-02-29 | $15.38M derived: sum of 3 quarters · filed 2012-02-29 | $20.68M derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $10.60M derived: sum of 2 quarters · filed 2012-02-29 | $15.90M derived: sum of 3 quarters · filed 2012-02-29 | $21.20M 10-K · filed 2012-02-29 |
| 2009-09-30 | $5.30M 10-Q · filed 2010-11-05 | $10.60M derived: sum of 2 quarters · filed 2010-11-05 | $15.90M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $5.30M 10-Q · filed 2010-08-06 | $10.60M 10-Q · filed 2010-08-06 | ||
| 2008-12-31 | $18.25M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |